Synthetic Biologics Inc. (AMEX:SYN) went down by -2.74% from its latest closing price compared to the recent 1-year high of $1.70. The company’s stock price has collected -2.45% of loss in the last five trading sessions. Press Release reported 17 hours ago that Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase
Is It Worth Investing in Synthetic Biologics Inc. (AMEX :SYN) Right Now?
Plus, the 36-month beta value for SYN is at 1.78. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Synthetic Biologics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $2.50. SYN currently public float of 129.71M and currently shorts hold a 0.01% ratio of that float. Today, the average trading volume of SYN was 1.45M shares.
SYN’s Market Performance
SYN stocks went down by -2.45% for the week, with a monthly drop of -11.25% and a quarterly performance of -20.34%, while its annual performance rate touched 32.42%. The volatility ratio for the week stands at 4.12% while the volatility levels for the past 30 days are set at 4.76% for Synthetic Biologics Inc.. The simple moving average for the period of the last 20 days is -4.68% for SYN stocks with a simple moving average of -29.46% for the last 200 days.
Analysts’ Opinion of SYN
Many brokerage firms have already submitted their reports for SYN stocks, with FBR & Co. repeating the rating for SYN by listing it as a “Outperform.” The predicted price for SYN in the upcoming period, according to FBR & Co. is $6 based on the research report published on January 06th of the previous year 2017.
FBR Capital, on the other hand, stated in their research note that they expect to see SYN reach a price target of $9, previously predicting the price at $10. The rating they have provided for SYN stocks is “Outperform” according to the report published on May 06th, 2016.
FBR Capital gave a rating of “Outperform” to SYN, setting the target price at $10 in the report published on February 26th of the previous year.
SYN Trading at -8.26% from the 50-Day Moving Average
After a stumble in the market that brought SYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.94% of loss for the given period.
Volatility was left at 4.76%, however, over the last 30 days, the volatility rate increased by 4.12%, as shares sank -12.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.80% lower at present.
During the last 5 trading sessions, SYN fell by -2.45%, which changed the moving average for the period of 200-days by -49.29% in comparison to the 20-day moving average, which settled at $0.4438. In addition, Synthetic Biologics Inc. saw 11.23% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at SYN starting from SHALLCROSS STEVEN A, who purchase 50,000 shares at the price of $0.49 back on May 10. After this action, SHALLCROSS STEVEN A now owns 100,000 shares of Synthetic Biologics Inc., valued at $24,595 using the latest closing price.
Stock Fundamentals for SYN
The total capital return value is set at -113.27, while invested capital returns managed to touch -87.12. Equity return is now at value -58.20, with -47.40 for asset returns.
Based on Synthetic Biologics Inc. (SYN), the company’s capital structure generated 5.89 points at debt to equity in total, while total debt to capital is 5.56.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.67.